Laurie Doyle
Investor Relations Kontakt bei GPC Biotech, Inc.
Profil
Ms. Laurie Doyle is a Director-Corporate Communications at GPC Biotech, Inc. and a Director-Corporate Communications at Transgene SA.
Ms. Doyle was previously employed as Senior Director-US Investor Relations by Agennix AG.
Aktive Positionen von Laurie Doyle
| Unternehmen | Position | Beginn |
|---|---|---|
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Laurie Doyle
| Unternehmen | Position | Ende |
|---|---|---|
| TRANSGENE | Public Communications Contact | - |
| AGENNIX AG | Public Communications Contact | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TRANSGENE | Health Technology |
| Private Unternehmen | 2 |
|---|---|
GPC Biotech, Inc.
GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
Agennix AG
 Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany. | Health Technology |
